<DOC>
	<DOCNO>NCT00089388</DOCNO>
	<brief_summary>This randomized phase II trial study well cilengitide work treat patient acute myeloid leukemia . Cilengitide may stop growth cancer cell block enzymes necessary growth</brief_summary>
	<brief_title>Cilengitide Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine 10-month relapse-free survival patient acute myeloid leukemia first complete remission treat cilengitide maintenance therapy . SECONDARY OBJECTIVES : I . Determine overall survival patient treated drug . II . Determine safety toxicity drug patient . III . Determine biological activity drug cell patient . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . Arm I : Patients receive cilengitide IV low dose 1 hour twice weekly 4 week . Arm II : Patients receive cilengitide IV high dose 1 hour twice weekly 4 week . In arm , course repeat every 4 week absence disease relapse unacceptable toxicity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia ( AML ) In first complete remission least 1 course induction chemotherapy AND 12 course consolidation chemotherapy newly diagnose AML , define follow : No evidence disease bone marrow Recovery peripheral blood count Platelet count &gt; 100,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Must able start study medication within 60 day start last consolidation therapy Must suitable donor , refuse , ineligible hematopoietic stem call transplantation None follow AML subtypes chromosomal translocation : Acute promyelocytic leukemia ( 8 ; 21 ) ( 16 ; 16 ) inv ( 16 ) Performance status ECOG 02 Performance status Karnofsky 60100 % See Disease Characteristics Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN Creatinine clearance &gt; 60mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No ongoing active infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness No prior investigational agent specifically designate antiangiogenic agent No concurrent prophylactic hematopoietic colonystimulating factor See Disease Characteristics Recovered prior consolidation chemotherapy No concurrent anticancer therapies No concurrent investigational cytotoxic agent</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>